🔗 Share this article

While the United States proceeds with historic changes to its vaccination guidelines, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines in the global health crisis and has focused upon alleged fatalities following COVID-19 vaccination in her short position at the FDA.

Planned Overhauls to Childhood Immunization Program

Health officials planned to unveil sweeping changes to the childhood immunization program in December, bringing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US at odds with much of the world with insufficient data for improved outcomes. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the drug and biologics divisions as Høeg and Prasad solidify control at the regulatory agency – and it suggests a increased emphasis upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for halting specific childhood shot schedules in the US so as to align more like Denmark, a society with universal health coverage and a population roughly the size of Wisconsin’s.

So far comments, she has kept her attention on vaccines – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Expertise

Høeg has no apparent background in pharmaceutical research, regulation or administrative roles, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past commissioners of CBER would “grasp legal statutes and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that former directors who led the center have had.”

This division has an enormous range of responsibilities at the FDA, she stated.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and every single one must be looked after,” she noted. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a major leadership component to the job, which oversees more than 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” Woodcock said.

Response and Disputed Initiatives

In response to questions about Høeg’s qualifications and whether this assignment indicates more teamwork among regulatory chiefs on immunizations, a spokesperson said that the “concerns stem from inaccurate premises”.

“Her resume matches the duties of her role,” the official said, citing the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s new priority voucher program, a controversial rapid drug-approval program that apparently troubled her predecessors. “By what process are these drugs being picked for this voucher program? Who is making the choices?” Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he said, “the FDA appears to be shifting towards more relaxed oversight of most medications, except for shots.”

Established History on Immunizations

With vaccines, Høeg has a more documented, if concerning, past, Howard said. She released a study using unconfirmed crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the new government included revising rules for new vaccines and ending “non-essential” vaccines, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has allegedly proposed preventing adolescent males from getting Covid vaccinations.

“She is an all-around true believer who begins with her conclusions and reverse-engineers to retrofit the science in a extremely misleading, fraudulent fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|